For most dermatologic conditions, my mantra for treatment tends to be “less is more”. I prefer to use the fewest number of creams, pills, and steps to achieve the best results. However, after watching this year’s ODAC Sneak Peek Inflammatory Diseases Symposium, I may have a new mantra for treating my rosacea patients – “forks, spoons, and knives”.
At the ODAC 2021 Pre-Conference Sneak Peek Inflammatory Diseases Symposium, Dr. Julie Harper, dermatologist at the Dermatology and Skin Care Center of Birmingham and Founding Director of the American Acne and Rosacea Society, built a case for use of combination therapy for rosacea. It is well known that there are four subtypes of rosacea – erythematotelangiectatic, papulopustular, phymatous, and ocular. However, most patients don’t fall into one subtype, but rather, many experience subtype overlap. This is why Dr. Harper believes that clinicians should “start subtyping lesions” and treat all the lesions that are observed, even if that means use of multiple therapeutic agents.
Not only are there multiple targets clinically, but treatment for rosacea can also be targeted on a cellular level. The role of innate immunity including cathelicidins, specifically LL-37, and toll-like receptor 2 induction via demodex has been described in the pathogenesis of rosacea. But did you know that many of the well-known triggers of rosacea such as heat, stress, exercise, and spice have been implicated to affect rosacea on a cellular level? I certainly didn’t! Dr. Harper explained that common triggers of rosacea cause neurogenic inflammation via induction transient receptor potential channels to release substance P and calcitonin gene-related peptide, which cause vasodilation.
Forks, Spoons, and Knives
To better understand therapeutic options, Dr. Harper compares the various treatments to utensils, categorizing them into forks, spoons, or knives. She states that treating rosacea is like eating a meal – you can’t get by with just one utensil. While a spork would be a plausible loophole to this one-utensil-meal challenge, we don’t quite have a spork for treating rosacea (yet!). So what exactly are the utensils that Dr. Harper explained?
Forks are medications that treat papules and pustules, including:
- Azelaic acid
- Sodium sulfacetamide/sulfur
- Modified release doxycycline
Spoons should be utilized for persistent background erythema, such as:
Finally, knives are device-based treatments:
- Pulsed dye laser
Why Combination Therapy?
Before showing us the evidence that combination therapy works, Dr. Harper described the goals of combination therapy:
- Achieve clear skin
- Achieve treatment goals more quickly
- Maximize remission periods
- Minimizing burden of disease
First, she reviewed a JDD article (Fowler J. J Drugs Dermatol. 2007;6(6)641-646) that combined two forks: modified release doxycycline and metronidazole gel. This 16-week study compared combination modified-release doxycycline with metronidazole 1% gel to metronidazole 1% gel with placebo. Metronidazole was discontinued at week 12 and doxycycline or placebo continued through week 16. At week 4, patients who received combination therapy had greater reduction of inflammatory lesion counts and were generally better faster. Then after week 12, those who continued on modified release doxycycline had better sustained results.
Next, Dr. Harper reviewed another JDD study (Stein Gold L, Papp K, et al. J Drugs Dermatol. 2017;16(9):909-916) that combined a fork and a spoon – ivermectin and brimonidine – to treat both moderate to severe erythematotelangiectatic and papulopustular rosacea. Three groups were identified in this study – one receiving vehicle only, one receiving ivermectin for 12 weeks with addition of bromonidine at week 4, and one receiving both ivermectin and brimonidine for 12 weeks. The most striking result from this study was that those who used combination therapy for 12 weeks had double the rate of improvement of redness in the three hours after brimonidine use. Dr. Harper explained that despite the use of a really good fork (ivermectin), there was still enough residual redness that the spoon (brimonidine) could make a meaningful impact. Thus, targeting inflammation and pustules alone will not lessen background erythema.
What’s New for Rosacea?
Finally, Dr. Harper reviewed some of the new medications for rosacea.
First is minocycline 1.5% foam, which has been shown to decrease inflammatory lesions significantly over 12 weeks of use when compared to vehicle. This phase 3 trial compared the use of minocycline 1.5% foam to vehicle for patients with moderate to severe rosacea. After 12 weeks, treatment success and reduction of inflammatory lesions was significantly higher for those who received minocycline foam.
Next, she reviewed 5% microencapsulated benzoyl peroxide cream. While not commercially available yet, phase 3 trials have shown promising results. The benefit of microencapsulated technology helps delay release of medication so that there is a lower risk of irritation in patients who already have known barrier dysfunction. When compared to vehicle, microencapsulated benzoyl peroxide had greater proportion of subjects that became “clear” or “almost clear” as well as greater reduction in inflammatory lesions after 12 weeks of use.
Since listening to Dr. Harper’s discussion on combination therapy, I have already put the utensil approach to use. (This can be confirmed by Dr. Adam Friedman!) And with promising new therapies on the horizon, I’m looking forward to seeing what new medications we can add to our utensil drawer to improve results for our rosacea patients.
This information was presented by Dr. Julie Harper at the 2021 ODAC Sneak Peek Inflammatory Diseases Symposium held on December 3rd, 2020. The above highlights from her lecture were written and compiled by Dr. Jessica Kalen, dermatology resident at the George Washington University School of Medicine and Health Sciences in Washington, DC.
All images courtesy of the Journal of Drugs in Dermatology.
Did you enjoy this article? Find more on Medical Dermatology here.